Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.


1 month+1.39% 3 years-3.22%
3 months+6.77% 5 years--
1 year+13.46% Since inception+15.09%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return--+17.28%
Expense ratio0.65%1.30%
Risk 5 year sharpe ratio0.761.02
Net assets$1.4B$3.1B
Average market cap$8.0B$10.4B
Average P/E--22.9
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--


U.S. stock94.92%
International stock2.77%
Fixed income0.56%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
CELG Celgene7.75%
ALXN Alexion Pharmaceuticals Inc7.57%
BIIB Biogen5.34%
VRTX Vertex Pharmaceuticals Inc4.35%
ILMN Illumina Inc4.32%
REGN Regeneron Pharmaceuticals4.24%
NBIX Neurocrine Biosciences Inc4.07%
INCY Incyte Corp3.71%
CLVS Clovis Oncology Inc3.36%
GILD Gilead Sciences3.32%